Related Experiment Video

Updated: May 19, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Primary hepatic amyloidosis: a mini literature review and five cases report

Ya-Dong Wang1, Cai-Yan Zhao, Hong-Zhu Yin

  • 1Department of Infectious Disease, Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.

Annals of Hepatology
|September 6, 2012
PubMed

Insights

Primary hepatic amyloidosis (PHA) involves abnormal protein deposits in the liver, often missed by doctors. Early diagnosis and treatment, like high-dose melphalan, are crucial for better outcomes in this rare liver disease.

Area of Science:

  • Hepatology
  • Immunology
  • Pathology

Background:

  • Primary hepatic amyloidosis (PHA) is a rare liver condition caused by abnormal deposition of monoclonal immunoglobulin light chains (AL).
  • The exact cause of PHA is not fully understood, and it is often misdiagnosed, leading to poor patient prognosis.
  • Hepatomegaly and elevated alkaline phosphatase (ALP) are common but lack specificity for PHA diagnosis.

Observation:

  • Congo Red staining of liver tissue is the current gold standard for diagnosing PHA.
  • Despite common clinical signs, specific diagnostic markers for PHA remain elusive.
  • Effective treatment strategies focus on reducing the production of amyloidogenic AL proteins.

Findings:

  • High-dose intravenous melphalan (HDM) and autologous stem cell transplantation (ASCT) are considered optimal therapies for PHA.
  • While HDM and ASCT show promise, their application in PHA treatment is still debated.
  • Further research is needed to clarify the pathogenesis and optimize therapeutic approaches for PHA.

Implications:

  • Improved diagnostic methods are needed to identify PHA earlier and more accurately.
  • Standardizing treatment protocols for PHA, including HDM and ASCT, could improve patient survival rates.
  • Understanding PHA pathogenesis may lead to novel therapeutic targets for this rare liver disease.

More Related Videos

Performing and Processing FNA of Anterior Fat Pad for Amyloid09:41

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Published on: October 30, 2010

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...